BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 15623701)

  • 1. Activation of humoral immunity and eosinophils in neuromyelitis optica.
    Correale J; Fiol M
    Neurology; 2004 Dec; 63(12):2363-70. PubMed ID: 15623701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chitinase effects on immune cell response in neuromyelitis optica and multiple sclerosis.
    Correale J; Fiol M
    Mult Scler; 2011 May; 17(5):521-31. PubMed ID: 21159721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-MOG autoantibodies in Italian multiple sclerosis patients: specificity, sensitivity and clinical association.
    Mantegazza R; Cristaldini P; Bernasconi P; Baggi F; Pedotti R; Piccini I; Mascoli N; La Mantia L; Antozzi C; Simoncini O; Cornelio F; Milanese C
    Int Immunol; 2004 Apr; 16(4):559-65. PubMed ID: 15039386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristic cerebrospinal fluid cytokine/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis.
    Matsushita T; Tateishi T; Isobe N; Yonekawa T; Yamasaki R; Matsuse D; Murai H; Kira J
    PLoS One; 2013; 8(4):e61835. PubMed ID: 23637915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.
    Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Trebst C; Ringelstein M; Aktas O; Winkelmann A; Buttmann M; Schwarz A; Zimmermann H; Brandt AU; Franciotta D; Capobianco M; Kuchling J; Haas J; Korporal-Kuhnke M; Lillevang ST; Fechner K; Schanda K; Paul F; Wildemann B; Reindl M;
    J Neuroinflammation; 2016 Sep; 13(1):279. PubMed ID: 27788675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Similar low frequency of anti-MOG IgG and IgM in MS patients and healthy subjects.
    Lampasona V; Franciotta D; Furlan R; Zanaboni S; Fazio R; Bonifacio E; Comi G; Martino G
    Neurology; 2004 Jun; 62(11):2092-4. PubMed ID: 15184621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Change in autoantibody and cytokine responses during the evolution of neuromyelitis optica in patients with systemic lupus erythematosus: A preliminary study.
    Kovacs KT; Kalluri SR; Boza-Serrano A; Deierborg T; Csepany T; Simo M; Rokusz L; Miseta A; Alcaraz N; Czirjak L; Berki T; Molnar T; Hemmer B; Illes Z
    Mult Scler; 2016 Aug; 22(9):1192-201. PubMed ID: 26514978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibodies against glycosylated native MOG are elevated in patients with multiple sclerosis.
    Gaertner S; de Graaf KL; Greve B; Weissert R
    Neurology; 2004 Dec; 63(12):2381-3. PubMed ID: 15623705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica.
    Rostásy K; Mader S; Hennes EM; Schanda K; Gredler V; Guenther A; Blaschek A; Korenke C; Pritsch M; Pohl D; Maier O; Kuchukhidze G; Brunner-Krainz M; Berger T; Reindl M
    Mult Scler; 2013 Jul; 19(8):1052-9. PubMed ID: 23257621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.
    Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S
    J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of brain-specific autoantibodies to myelin oligodendrocyte glycoprotein, S100beta and myelin basic protein in patients with Devic's neuromyelitis optica.
    Haase CG; Schmidt S
    Neurosci Lett; 2001 Jul; 307(2):131-3. PubMed ID: 11427318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study.
    Kitley J; Waters P; Woodhall M; Leite MI; Murchison A; George J; Küker W; Chandratre S; Vincent A; Palace J
    JAMA Neurol; 2014 Mar; 71(3):276-83. PubMed ID: 24425068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype.
    Pröbstel AK; Rudolf G; Dornmair K; Collongues N; Chanson JB; Sanderson NS; Lindberg RL; Kappos L; de Seze J; Derfuss T
    J Neuroinflammation; 2015 Mar; 12():46. PubMed ID: 25889963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders.
    Banwell B; Tenembaum S; Lennon VA; Ursell E; Kennedy J; Bar-Or A; Weinshenker BG; Lucchinetti CF; Pittock SJ
    Neurology; 2008 Jan; 70(5):344-52. PubMed ID: 18094334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum antibodies to 25 myelin oligodendrocyte glycoprotein epitopes in multiple sclerosis and neuromyelitis optica: clinical value for diagnosis and disease activity.
    Xu Y; Zhang Y; Liu CY; Peng B; Wang JM; Zhang XJ; Li HF; Cui LY
    Chin Med J (Engl); 2012 Sep; 125(18):3207-10. PubMed ID: 22964310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome.
    Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Ringelstein M; Trebst C; Winkelmann A; Schwarz A; Buttmann M; Zimmermann H; Kuchling J; Franciotta D; Capobianco M; Siebert E; Lukas C; Korporal-Kuhnke M; Haas J; Fechner K; Brandt AU; Schanda K; Aktas O; Paul F; Reindl M; Wildemann B;
    J Neuroinflammation; 2016 Sep; 13(1):280. PubMed ID: 27793206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased interleukin-6 correlates with myelin oligodendrocyte glycoprotein antibodies in pediatric monophasic demyelinating diseases and multiple sclerosis.
    Horellou P; Wang M; Keo V; Chrétien P; Serguera C; Waters P; Deiva K
    J Neuroimmunol; 2015 Dec; 289():1-7. PubMed ID: 26616865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuromyelitis optica-IgG in idiopathic inflammatory demyelinating disorders amongst Hong Kong Chinese.
    Chan KH; Ramsden DB; Yu YL; Kwok KH; Chu AC; Ho PW; Kwan JS; Lee R; Lim E; Kung MH; Ho SL
    Eur J Neurol; 2009 Mar; 16(3):310-6. PubMed ID: 19138340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relevance of antibodies to myelin oligodendrocyte glycoprotein in CSF of seronegative cases.
    Mariotto S; Gajofatto A; Batzu L; Delogu R; Sechi G; Leoni S; Pirastru MI; Bonetti B; Zanoni M; Alberti D; Schanda K; Monaco S; Reindl M; Ferrari S
    Neurology; 2019 Nov; 93(20):e1867-e1872. PubMed ID: 31645473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Novel Approach to Discriminate Subgroups in Multiple Sclerosis.
    Farrokhi M; Saadatpour Z; Fadaee E; Saadatpour L; Rezaei A; Moeini P; Amani Beni A
    Iran J Allergy Asthma Immunol; 2016 Dec; 15(6):536-546. PubMed ID: 28129686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.